- 7023 malaria professionals are enjoying the free benefits of MalariaWorld today

Who's online
There are currently 4 users and 232 guests online.
Online users
- Inga
- Moon
- patrick sampao
- Kabogo
News Flash
Latest Jobs
Events 2010
Recent blog posts
- Job: Postdoctoral Fellow: Malaria transmission-blocking research (Entomologist/Malariologist)
- Job: ACT Consortium Policy Liaison Officer
- Harnessing Immunity Genes Against Plasmodium: The Series
- We thought we were down to 655.000 deaths in 2010, right?
- Job: Postdoctoral Fellow: Malaria resistance research
- Let the sun shine
- Postdoctoral Fellows: Malaria research
- Guest Editorial: Don't fake it!
- Loop mediated amplification question
- Criticism, Ideas and the Maya example
For subunit vaccines, adjuvants play a key role in shaping immunological memory.
Our results showed that its sensitivities for P. falciparum, P. vivax, and mixed-species infection were 96.5%, 95.3%, and 85.7%, respectively. In addition, its specificity was high (99.4%).
The study highlights the safety and immunological benefits of DiCo mix as a potential human vaccine against blood stage malaria, especially when formulated in CoVaccine HTTM, and adds to the accumulating data on the specificity broadening effects of DiCo mix.
Malaria presents a challenge to world health that to date has been beyond the abilities of researchers to conquer.
n malaria endemic regions, a fetus is often exposed in utero to Plasmodium falciparum blood-stage Ags.
The concept of a malaria vaccine has sparked great interest for decades; however, the challenge is proving to be a difficult one.
Our study suggests that schistosomiasis coinfection favours anti-malarial protective antibody responses, which could be associated with the regulation of IL-10 and IFN-γ production and seems to be antigen-dependent.
Results presented here show that immunoglobulin GM allotypes contribute to the natural antibody responses to P. vivax malaria antigens. These findings have important implications for the effectiveness of vaccines containing PvAMA-1 or PvMSP1-19 antigens.